Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1990 May;85(5):1666-71.
doi: 10.1172/JCI114618.

Regulation of immunoglobulin (Ig)E synthesis in the hyper-IgE syndrome

Affiliations

Regulation of immunoglobulin (Ig)E synthesis in the hyper-IgE syndrome

D Vercelli et al. J Clin Invest. 1990 May.

Abstract

The hyper-IgE (HIE) syndrome is characterized by high IgE serum levels, chronic dermatitis, and recurrent infections. The mechanisms responsible for hyperproduction of IgE in HIE patients are presently unknown. We investigated whether spontaneous in vitro IgE synthesis by PBMC from seven HIE patients was sensitive to signals (cell adhesion, T/B cell cognate interaction and lymphokines: IL-4, IL-6, and IFN-gamma) known to regulate IgE induction in normals. Our results show that, unlike IL-4 dependent IgE synthesis induced in normals, spontaneous IgE production by PBMC from HIE patients was not blocked by monoclonal antibodies to CD2, CD4, CD3, and MHC class II antigens. Furthermore, antibodies to IL-4 and IL-6 did not significantly suppress IgE production. IFN-gamma had no significant effects on spontaneous in vitro IgE synthesis. To test whether an imbalance in lymphokine production might underlie hyperproduction of IgE in HIE patients, mitogen-induced secretion of IL-4 and IFN-gamma by PBMC was assessed. No significant difference was detected between HIE patients and normal controls. Thus, ongoing IgE synthesis in the HIE syndrome is largely independent of cell-cell interactions and endogenous lymphokines, and is due to a terminally differentiated B cell population, no longer sensitive to regulatory signals.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Hematol Oncol Clin North Am. 1988 Mar;2(1):81-100 - PubMed
    1. Immunodefic Rev. 1989;1(2):155-72 - PubMed
    1. J Immunol. 1988 Jun 15;140(12):4193-8 - PubMed
    1. Eur J Immunol. 1988 Jun;18(6):929-35 - PubMed
    1. J Immunol. 1988 Aug 15;141(4):1218-24 - PubMed

Publication types